Connect with us

Published

on

Due to the imminent threat of climate change and expected legal measures, companies across different sectors are increasingly driven to set and actively pursue sustainability objectives.

The pharmaceutical sector, faced with rising stakeholder expectations and tightening regulations, is accelerating efforts to reduce its environmental impact. Several major players in the industry have committed to achieving net-zero emissions as their climate sustainability target. These leading pioneers are blazing the trail by implementing policies and undertaking initiatives, including the purchase of carbon credits, to accomplish this ambitious objective.

 

The pharmaceutical industry’s carbon footprint

The pharmaceutical sector is a significant contributor to global emissions. If it were a country, its carbon footprint would rank 9th in the world. Energy-intensive manufacturing processes, extensive distribution networks, and greenhouse gas-emitting propellants in inhalers drive up the industry’s climate impacts. Experts urge pharmaceutical companies to act, as unmitigated warming could strain global health systems and hinder access to vital medications.

While daunting, the mission is not impossible. Industries like tech and retail are demonstrating that reaching net-zero is within grasp. Google aims to run entirely on carbon-free energy by 2030. IKEA plans to become climate positive by 2030 by reducing more greenhouse gas emissions than its value chain emits. These commitments raise the bar for pharmaceutical companies to take equally bold climate action.

Major industry players are stepping up. AstraZeneca, Novartis, and Takeda have set ambitious net-zero targets, while investing in renewable energy, green chemistry innovation, and carbon removal. Their efforts are having ripple effects as peers follow suit. With collaboration and persistence, the pharmaceutical industry can curb its emissions in line with climate science.

 

AstraZeneca’s U$1BN of climate commitments

With over $26 billion in annual revenue, British-Swedish firm AstraZeneca is one of the world’s largest pharmaceutical companies. It manufactures blockbuster treatments ranging from diabetes to oncology medications.

In 2020, AstraZeneca announced its Ambition Zero Carbon strategy, aiming to achieve carbon neutrality across its entire value chain by 2030. This bold pledge puts AstraZeneca at the vanguard of climate action in pharma.

To meet its goal, AstraZeneca is transitioning to 100% renewable electricity at its sites by 2025. It is also optimizing manufacturing to curb emissions, while partnering with suppliers to reduce their carbon footprints. Further, AstraZeneca plans to eliminate fossil fuel vehicles from its fleet by 2030.

Beyond its operations, AstraZeneca is developing a portfolio of over $1 billion in green investments. These include carbon removal and storage solutions expected to offset about 2.5 million tonnes of CO2 annually by 2025.

AstraZeneca’s commitment is spurring the industry to accelerate sustainability initiatives. Being the pioneer in the pharmaceutical industry to establish a bold net-zero objective that encompasses its entire value chain, AstraZeneca is setting a remarkable example that its competitors will have to strive to emulate.

 

Novartis to use 100% renewable energy within 2023

Headquartered in Switzerland, Novartis is a leading global medicines company with over $48 billion in 2021 revenue. Its therapeutic areas span eye care, immunology, and cardiovascular treatments.

In 2021, Novartis announced its aim to achieve carbon neutrality across Scopes 1, 2, and 3 by 2040. Scope 1 and 2 cover direct emissions from Novartis’ operations, while Scope 3 includes indirect emissions across its supply chain.

Novartis’ environmental policies are publicly available on the internet. The company has made meeting its net-zero ambition a top priority, with a strong and focused approach in four crucial areas: sourcing renewable electricity, enhancing energy efficiency, promoting innovative green chemistry, and investing in carbon removal offsets.

Already, Novartis sources 80% of its electricity from renewables. It is also optimizing production processes, deploying automation, and modifying fleet vehicles to curb emissions. The company is on track to source 100% of its power from renewables by years’ end of 2023.

Additionally, Novartis is pioneering molecular design techniques to develop medicines with lower environmental impacts. Furthermore, the company is actively investing in projects that focus on nature-based carbon removal, such as collaborating with Carbon Direct to expand the implementation of carbon forestry offsets.

By setting and working toward net-zero science-based targets, Novartis is positioning itself as a leader in green pharmaceutical manufacturing. Its multipronged approach can serve as a model for other companies.

 

Takeda Pharmaceuticals shows the way for Asia

Japan’s largest pharmaceutical company, Takeda Pharmaceutical generates over $30 billion in annual revenue from medicines treating conditions from cancer to rare diseases.

In 2021, Takeda announced its commitment to achieving net-zero greenhouse gas emissions by 2040. It is working to reduce and offset its entire carbon footprint, including Scope 3 emissions from its supply chain.

Takeda is achieving its goal by increasing renewable electricity usage, improving energy efficiency at its sites, electrifying its vehicle fleet, and reducing emissions from business travel. It aims to cut Scopes 1 and 2 emissions 46% by 2030.

Takeda is also collaborating with pharmaceutical industry partners and suppliers to curb emissions across its value chain under the Pharmaceutical Supply Chain Initiative. And it plans to utilize carbon removal offsets for hard-to-abate emissions.

Takeda’s pledge to achieve net-zero marks a groundbreaking moment for the pharmaceutical industry in Asia and beyond, as they lead the charge towards comprehensive decarbonization. Its 2040 target and interim science-based milestones demonstrate meaningful leadership.

 

Pharma’s challenges in reaching net-zero

Despite strong commitments from sustainability front-runners, achieving net-zero emissions poses complex challenges for pharmaceutical companies. Many production processes inherently rely on fossil fuels as heat sources and for transporting materials. Companies need major capital investments to transition these operations to clean energy alternatives.

Pharmaceutical distribution and long, complex supply chains also make emissions reductions difficult. Cold chain storage and last-mile delivery result in substantial greenhouse gas outputs. Meanwhile, developing green chemistry solutions requires years of research and development, along with new manufacturing infrastructure. These costs can be prohibitive. Further, credibly offsetting all residual emissions will necessitate scaled up, verifiable carbon removal markets. Technical and economic hurdles remain for many offset types.

 

Overcoming Challenges

While obstacles exist, experts emphasize they can be solved through collaboration, innovation, and policy action.

Companies can join forces and share their knowledge and resources through initiatives like the Pharmaceutical Supply Chain Initiative. This collaboration enables them to not only expand their renewable energy procurement, but also boost their efficiency and make strides in green chemistry.

Governments can help by offering incentives for clean technology investments and funding research into pharmaceutical process improvements.

International cooperation can accelerate decarbonization of global supply chains. And standardized offset methodologies will ensure carbon removal credits have integrity.

Ultimately, reaching net-zero will depend on persistence, investment, and cross-industry partnership. But the health and environmental benefits make it imperative for pharmaceutical companies to see it through.

 

Opportunities from net-zero efforts

Pursuing net-zero also opens up opportunities for pharmaceutical companies to add business value, beyond environmental benefits. Optimizing processes for energy efficiency provides cost savings from reduced power consumption and heating needs. Streamlining supply chains also cuts costs over the long-term.

First movers on net-zero can boost their reputations with consumers and investors, who increasingly prioritize sustainability. These companies may have better talent recruitment and retention.

Developing and marketing lower carbon medicines can become a competitive advantage. Doctors and health systems are paying more attention to the climate footprint of drugs.

AstraZeneca’s partnerships have the potential to unlock opportunities for companies to venture into the burgeoning green investment markets. Through these collaborations, businesses can not only contribute to the sustainability of our planet but also reap financial benefits by investing in carbon removal and renewable energy projects.

Finally, building climate resilience helps ensure business continuity as physical impacts of climate change accelerate.

 

Government policy propels climate action

Governments are ramping up policies aimed at decarbonizing pharmaceutical value chains through incentives and requirements.

The Inflation Reduction Act of 2022 in the United States presents an extraordinary opportunity, providing over $60 billion in incentives dedicated to fostering energy efficiency, electrification, and groundbreaking advancements in green chemistry. This can offset costs for companies pursuing these strategies.

The EU’s pharmaceutical strategy aims to make drug manufacturing and distribution more sustainable by implementing green product design and procurement requirements. This will help reduce emissions.

India released a roadmap in 2022 pushing pharmaceutical companies to adopt renewable energy and assess Scope 3 climate impacts. It aims to help India meet its national climate targets.

Such policies encourage pharmaceutical companies to take ownership of their emissions and are likely to expand as more governments declare net-zero commitments.

 

The Road Ahead

While the 2030s and 2040s may seem like distant milestones, reaching net-zero requires immediate action across pharmaceutical supply chains. Industry leaders have provided a blueprint – including renewable energy procurement, distribution optimization, green chemistry, and carbon removal.

New technologies and nature-based solutions are expanding decarbonization opportunities. With collective willpower, strategic investment, and transparent reporting, net-zero is within the pharmaceutical industry’s reach. All stakeholders must maintain pressure and hold firms accountable to their pledges for a sustainable future.

 

Photo credit

Photo by Myriam Zilles on Unsplash

Carbon Footprint

Trump EPA’s Largest Climate Deregulation: What the 2009 “Endangerment Finding” Repeal Means for U.S. Emissions and the EV Market

Published

on

On February 12, President Donald Trump and the U.S. Environmental Protection Agency (EPA) Administrator Lee Zeldin announced what they called the largest deregulation in U.S. history in the White House’s Roosevelt Room.

The EPA finalized a rule that removes the 2009 Greenhouse Gas (GHG) Endangerment Finding. The Obama administration created this finding, and it gave the federal government the legal authority to regulate greenhouse gas emissions under the Clean Air Act for more than a decade.

The new rule also removes all federal greenhouse gas standards for cars, trucks, and engines built from model year 2012 through 2027 and beyond. In addition, the EPA ended compliance credits tied to certain technologies, including start-stop systems.

In short, the administration rolled back the key rule that supported federal climate regulations on vehicles.

The Role of the 2009 Endangerment Finding

In 2009, the EPA said that six major greenhouse gases—including carbon dioxide—harm public health and the environment. The agency concluded that these gases drive climate change and damage air quality. That decision gave the federal government the authority to set emission limits for light-, medium-, and heavy-duty vehicles. It also supported climate rules for power plants and the oil and gas industry.

Because of this finding, the EPA introduced several greenhouse gas standards over the past decade. These rules shaped vehicle design, fuel economy targets, and broader climate policy across multiple sectors.

Why the EPA Repealed It Now

In 2025, the Trump administration began reviewing the 2009 decision. Officials argued that some of the science behind the finding was weaker than originally believed. They also said earlier climate projections were too pessimistic.

Now that the repeal is final, the EPA says it no longer has authority under Section 202(a) of the Clean Air Act to regulate greenhouse gases the way it did before. The agency believes Congress—not federal regulators—should decide major climate policy.

EPA leaders say this move restores a strict reading of the law and ends what they call regulatory overreach. Critics strongly disagree. Many scientists and public health experts argue that the repeal removes an important tool that protects Americans and helps address climate change.

Most importantly, the EPA estimates the final rule will save more than $1.3 trillion. It removes requirements for automakers to measure, report, certify, and comply with federal greenhouse gas standards. The agency says the rollback will lower vehicle prices, expand consumer choice, and reduce transportation costs for families and businesses.

Administrator Zeldin commented,

“The Endangerment Finding has been the source of 16 years of consumer choice restrictions and trillions of dollars in hidden costs for Americans. Referred to by some as the ‘Holy Grail’ of the ‘climate change religion,’ the Endangerment Finding is now eliminated. The Trump EPA is strictly following the letter of the law, returning commonsense to policy, delivering consumer choice to Americans and advancing the American Dream. As EPA Administrator, I am proud to deliver the single largest deregulatory action in U.S. history on behalf of American taxpayers and consumers. As an added bonus, the off-cycle credit for the almost universally despised start-stop feature on vehicles has been removed.”

U.S. Emissions Trends in 2025: Mixed Signals

At a climate crossroads, the United States saw a rebound in greenhouse gas emissions in 2025 after years of overall decline. According to estimates from the Rhodium Group, total U.S. emissions rose about 2.4% in 2025, reaching roughly 5.9 billion tons of CO₂ equivalent—139 million tons higher than in 2024. This uptick ended a two‑year downward trend that had been driven by cleaner energy and transportation shifts.

us emission

Several factors pushed emissions higher: colder winter weather increased demand for heating; rising electricity demand from data centers and cryptocurrency mining boosted fossil fuel use; and higher natural gas prices led utilities to burn more coal. The power sector alone saw a 3.8% rise in emissions, while buildings’ emissions jumped 6.8%. Transportation emissions, the largest U.S. source, remained largely flat, increasing only modestly due to continued adoption of hybrid and electric vehicles.

us emissions

Despite the 2025 increase, total emissions are still below pre‑pandemic levels and well under 2005 baselines—roughly 18% below 2005 levels—showing that long‑term trends toward decarbonization have not entirely reversed yet.

Preliminary sector data from Climate TRACE also indicates that U.S. emissions continued rising throughout 2025, adding more than 71 million tonnes of CO₂ equivalent through the first three quarters of the year.

The EV Market in 2025: Growth and Slowdowns

In contrast to emissions trends, the U.S. electric vehicle (EV) market continued to grow in 2025, though the pace and dynamics evolved. EVs made notable gains in sales and market share, reflecting both consumer demand and industry transitions.

In the first quarter of 2025, nearly 300,000 battery‑electric vehicles were newly registered, marking over a 10% year‑over‑year increase. EVs accounted for about 7.5% of all new car registrations during that period.

By the third quarter, sales surged again. Cox Automotive reported that EV sales jumped nearly 30% year‑over‑year, pushing EV market share to a record 10.5% of total vehicle sales in Q3 2025—a milestone reflecting strong consumer uptake in several segments.

ev sales
source: Cox Automotive

Even so, EV adoption remains far from dominating the U.S. market. Estimates show that electric vehicles comprised around 8–10% of total U.S. new car sales in 2025, with internal‑combustion engine vehicles still accounting for the large majority of the fleet.

Tesla remained the largest EV brand in the U.S. in 2025, holding about 46% market share, though this marked a slight decline from previous years. Rivals like Chevrolet and Hyundai grew their shares, reflecting broader model availability and shifting consumer preferences.

Market analysts also project that by 2025, the U.S. EV market’s size, sales, and technology focus will continue expanding—with battery‑electric vehicles expected to dominate EV segments. The broader EV market size had substantial growth in 2025, with further expansion expected toward the end of the decade.

us ev market

Balancing Regulation, Consumer Choice, and Emissions Goals

EPA officials say that removing federal GHG standards and related compliance credits will lower vehicle costs by about $2,400 per car. This will ease financial pressure on families and businesses and give buyers more choice. The agency calls it a step toward restoring the American Dream, making transportation more affordable without high regulatory costs.

Supporters argue the rollback removes artificial mandates, letting automakers and consumers focus on market-driven solutions. The EPA also ended “off-cycle” credits, which allowed carmakers to meet emission targets with minor technology changes. Critics called these credits gimmicks with little real environmental benefit.

Litigation and Future Policy

Environmental groups, scientists, and several states sharply criticized the move. They warn that it weakens climate action, public health protections, and emission reductions. Many fear that removing these rules while emissions are rising could set back U.S. climate goals.

Legal challenges are expected, with lawsuits likely to block or reverse the repeal. As federal rules change, state policies, corporate commitments, and Congress may play a larger role. Some states have already set carbon standards and EV incentives, creating a patchwork of climate policies across the country.

In conclusion, the 2026 repeal of the GHG Endangerment Finding marks a major shift in U.S. climate policy. With emissions rising and clean technology markets evolving, the country faces tough choices about balancing economic growth, innovation, and climate risk. The coming years will be shaped by lawsuits, state leadership, private investments, and the global move toward low-carbon economies.

The post Trump EPA’s Largest Climate Deregulation: What the 2009 “Endangerment Finding” Repeal Means for U.S. Emissions and the EV Market appeared first on Carbon Credits.

Continue Reading

Carbon Footprint

DECARBON 2026 Concludes with Two Days of Strategic Debate and Practical Decarbonisation Insights

Published

on

Hosted by Shell and held in partnership with Moeve, Fluor, Gasunie, The International Association of Oil & Gas Producers, Repsol, Spiecapag and Germany Trade and Invest, DECARBON 2026 centred on practical decision-making at the intersection of policy, technology and implementation across the oil and gas value chain in Vösendorf, Austria.

On 9 February, the first day opened with an Executive Opening Panel that set the strategic context for DECARBON by linking emissions targets with the operational capabilities required to deliver them. Drawing on perspectives from Petro IT, Shell Austria, Saipem SpA, Austrian Gas Grid Management AG, Chromalox, NEUMAN & ESSER Deutschland GmbH & Co KG and PCK Raffinerie GmbH, the discussion addressed investment priorities, data-driven decision-making and on-site constraints, clarifying why a strategic approach and clearly defined NetZero targets play a central role in modern oil and gas operations.

As Rainer Klöpfer, Country Chair & Managing Director at Shell Austria, emphasised, the conversation around net-zero must account for the full carbon intensity of energy products, spanning production, supply chains and end use. He underlined that operating plans are updated regularly and reflect today’s economic realities, while long-term net-zero targets sit beyond immediate planning cycles and require steady structural progress. This perspective shifted the focus from ambition to execution and naturally opened the floor to the next strategic question: which concrete low-carbon solutions can integrate into existing systems at scale.

This was followed by the Leaders Panel on low-carbon hydrogen as a decarbonisation tool, with contributions from a broad range of energy, infrastructure and technology players, including MOL Group, Eurogas, NextChem, Alléo Energy, Moeve and Italgas Reti. The panel examined hydrogen’s role within decarbonisation strategies and its interaction with existing infrastructure and regulatory frameworks.

Pedro Medina, Hydrogen Technology Manager at Moeve, outlined the company’s transformation of its refineries in San Roque and Palos de la Frontera into diversified energy parks adapted for renewable fuels, including biofuels and green hydrogen. He emphasised Southern Europe’s strong production potential and referred to the development of European hydrogen corridors connecting hubs such as Huelva and Algeciras with

Rotterdam, illustrating how green hydrogen is taking shape as a cross-border value chain within the evolving European energy landscape.

The conversation then continued through two roundtable discussions. The first roundtable on the digital approach to emissions performance brought together representatives from Siemens AG, Gradyent and other industry participants to explore digitalisation, automation and data-driven sustainability initiatives. The next roundtable on institutional readiness, with participants from Wood, OPEC, OGE and others, addressed regulatory risk, compliance requirements and policy developments.

Day One also featured two thematic sessions examining decarbonisation pathways in downstream operations through low-carbon fuels and feedstock, alongside practical levers for emissions reduction in upstream activities, with contributions from companies including TotalEnergies, Chromalox, VEM Sachsenwerk GmbH and others.

It concluded with a gala dinner and prize draw at Casino Baumgarten, located in the heart of Vienna. Live music, a magician’s performance and a gift raffle from BGS Group and participating delegates created a vibrant atmosphere, while conversations continued over dinner in an informal setting that strengthened professional connections.

The second day moved the discussion toward evaluation and optimisation, bringing sharper focus to cost, performance and implementation. During a moderated debate, representatives of Reganosa, Saras, Gas Infrastructure Europe and The Carbon Capture and Storage Association examined the financial implications of decarbonisation and the investment logic behind transition pathways. Roundtable 3 then turned to energy efficiency in downstream, where Fluor, Akselos and other sector specialists shared operational case studies and technical insight. The Congress concluded with a Closing Panel on CCUS, featuring perspectives from Petrofac, DESFA, Worley Comprimo and others, highlighting carbon capture, utilisation and storage within long-term emissions reduction strategies.

Phillip Cooper, Project Director at Petrofac for the Design of the Aramis CCS Pipeline System, summarised the key lesson from project delivery: effective CCS development requires a collaborative and knowledgeable client and FEED team in the room from the outset to ensure alignment and accelerate resolution. He stressed that system engineering across the entire value chain is critical, as the whole system must function as one despite contractual boundaries, and that early involvement of contractors and vendors is essential to understand what the project will realistically cost and to avoid unnecessary cost premiums.

Over the two days, DECARBON 2026 reinforced its role as a closed-door platform for senior executives, technical leaders and policy experts to engage in implementation-oriented dialogue grounded in real operational contexts. More than 180 pre-arranged B2B sessions took place within a structured networking format, coordinated by dedicated personal managers assigned to each delegate. Participants highlighted the productivity and efficiency of these targeted exchanges, with many confirming follow-up discussions and outlining future joint projects.

Registration for DECARBON 2027, taking place on 15-16 February 2027 in Berlin, Germany, is now open. Follow the Congress updates and secure participation in the next edition focused on real-world decarbonisation strategies: https://sh.bgs.group/3ui

The post DECARBON 2026 Concludes with Two Days of Strategic Debate and Practical Decarbonisation Insights appeared first on Carbon Credits.

Continue Reading

Carbon Footprint

Albemarle Shuts Lithium Plant But Bets Big on Strong Demand Outlook for 2026

Published

on

Albemarle Shuts Lithium Plant But Bets Big on Strong Demand Outlook for 2026

Albemarle Corporation, one of the world’s largest lithium producers, has closed its Kemerton lithium hydroxide processing plant in Western Australia. The company made the decision due to rising costs and competitive pressures in hard-rock lithium processing. The closure affects more than 250 jobs and dozens of contractors.

The Kemerton plant processed lithium from the Greenbushes mine and was intended to supply battery-grade lithium chemicals. Albemarle invested over US$4 billion in the site, but the facility never reached its target performance. The company cited structural challenges and higher operating costs compared with plants in China.

The shutdown highlights difficulties in building competitive lithium processing outside China. China currently dominates lithium refining and battery supply chains. Many Western firms have struggled to build profitable chemical conversion capacity, even with recent lithium price improvements.

Solid Earnings, Shaky Investor Sentiment

Albemarle reported its fourth-quarter and full-year 2025 earnings in mid-February 2026. The company posted net sales of US$1.4 billion, up about 16% year-on-year, driven by growth in energy storage volumes and pricing. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) rose about 7% compared with 2024.

Albemarle financial results 2025
Source: Albemarle

Despite these positive metrics, Albemarle’s stock fell sharply after the earnings release. Morningstar reported that on February 12, 2026, shares fell about 7%. This drop happened during a wider market sell-off. Still, the company’s profit outlook was better than what analysts expected.

Albemarle stock price

Investors reacted to a mixed message from the earnings data. The company had sales growth and strong cash flow. However, the closure of the Kemerton plant and ongoing cost pressures affected sentiment. Some investors were cautious about near-term guidance amid global market volatility.

But Management Bets on a 2026 Demand Rebound

Despite short-term pressures, Albemarle’s management outlined a strong demand outlook for lithium in 2026. In a recent earnings call, company leaders projected that global lithium demand could grow by 15% to 40% in 2026.

Albemarle lithium demand outlook
Source: Albemarle

This growth is driven in part by a sharp rise in stationary energy storage demand and continued EV adoption. Stationary storage includes large battery systems used for grid balancing, renewable energy smoothing, and data centers. These systems are becoming major new consumers of lithium-ion batteries.

Industry reports say global energy storage installations more than doubled in 2025. This rise shows growing demand, extending beyond just electric vehicles.

global energy storage market 2025
Source: Wood Mackenzie

Albemarle also reported that its free cash flow in 2025 was about US$692 million after cost controls and capital discipline. The company plans to keep capital expenditures steady in 2026. It will focus on boosting productivity and developing resources instead of expensive expansion projects.

EVs and Grid Storage Keep the Battery Boom Alive

Lithium is a key metal for lithium-ion batteries. These batteries power electric vehicles (EVs), grid storage systems, portable electronics, and more.

Electric vehicle adoption continues to grow globally. The International Energy Agency says EV sales hit around 20 million units in 2025. This makes up nearly 25% of all car sales globally. EVs alone account for about 75% of total lithium demand in 2025 in battery markets.

In addition, stationary energy storage systems are becoming more common. Battery storage helps balance renewable energy like wind and solar on the grid. Storage growth is part of broader climate and energy policies in many countries.

  • Demand growth is also supported by new battery applications, such as data centers and backup power systems.

Some market analysts expect global lithium demand to more than double by the decade’s end. This will depend on EV adoption rates, renewable energy growth, and storage needs.

Processing Bottlenecks and Price Swings Complicate Supply

While demand is rising, the supply side of lithium faces challenges.

Mining output increased sharply between 2021 and 2025. Australia, Chile, and China expanded production during that period. However, processing capacity, especially outside China, has lagged.

2025 lithium global production

The closure of Albemarle’s Kemerton plant underscores these supply constraints. Western plants face higher labor, energy, and infrastructure costs compared with counterparts in China. These factors make lithium hydroxide production less profitable in some regions.

China dominates downstream lithium processing and battery cell production. The country holds 60–70% of the world’s lithium chemical processing capacity. It also makes around 75% of lithium-ion batteries, based on data from the International Energy Agency.

At the same time, some supply projects have delayed expansion, held back by financing costs, permitting hurdles, and fluctuating prices.

Price volatility has been a feature of the lithium market over the past few years. After reaching multiyear highs in 2022, lithium carbonate prices plunged through 2023 and 2024 due to oversupply. Prices bounced back in late 2025 and further skyrocketed in early 2026.

lithium carbonate spot price

Cost Cuts and Capital Discipline Take Center Stage

Albemarle’s recent actions illustrate how lithium producers respond to shifting conditions.

The company cut costs, lowered capital spending, and sold non-core assets to boost its balance sheet. These moves helped Albemarle generate strong free cash flow even with price swings.

Management noted cost and productivity gains of US$100–150 million aimed for 2026. This will help boost profit margins, particularly in energy storage segments.

Albemarle’s strategy focuses on maintaining stable operations while positioning for long-term demand growth. This includes optimizing asset portfolios, managing supply chains, and shifting production toward lower-cost channels.

Other companies in the lithium sector are also adapting. Some are concentrating on mining expansions, processing partnerships, and technology improvements. Others are exploring recycling and alternative battery chemistries to reduce reliance on lithium.

Miners like Pilbara Minerals, SQM, and Sigma Lithium are expanding and optimizing supply. They do this to stay competitive during price cycles. Refiners like Ganfeng Lithium and Tianqi Lithium are expanding their conversion capacity. They are also integrating their supply chains.

Moreover, firms like Standard Lithium and EnergyX are developing direct lithium extraction methods. These aim to boost recovery and lower water impacts. Recycling companies like Redwood Materials, Li-Cycle, and Umicore are expanding systems. They recover lithium and other metals from used batteries.

Battery makers such as CATL are also investing in sodium-ion technology, which can reduce lithium demand in some market segments.

A Tightening Market in the Making?

The lithium market continues to evolve. There are signs of a structural shift as demand grows faster than supply in some scenarios.

Analysts expect that demand from EVs and energy storage will keep pushing lithium consumption up for the rest of the decade. Albemarle’s plant closure shows that supply issues and processing challenges might tighten the market. This could happen if new capacity isn’t ready soon.

Long-term forecasts suggest many countries and companies will need secure lithium sources. They will also need more downstream processing capacity to meet climate and clean energy goals.

For Albemarle, the mix of cost discipline, demand growth forecasts, and strategic positioning could help the company navigate a market that is both dynamic and competitive.

The post Albemarle Shuts Lithium Plant But Bets Big on Strong Demand Outlook for 2026 appeared first on Carbon Credits.

Continue Reading

Trending

Copyright © 2022 BreakingClimateChange.com